Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis

Journal of Neuroimmunology

Volumn 117, Issue 1-2, 2001, Pages 156-165

  Makhlouf, Karim ^a   Comabella, Manuel ^b   Imitola, Jaime ^a   Weiner, Howard L ^a   Khoury, Samia J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

2 agonists; Cytokines; Human; Multiple sclerosis; Salbutamol; Th1 Th2

Indexed keywords

INTERLEUKIN 12; SALBUTAMOL;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANTIGENS, CD40; ANTIGENS, CD80; BUCLADESINE; DENDRITIC CELLS; FEMALE; HUMANS; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS;

EID: 0035796770     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(01)00322-8     Document Type: Article

References (41)

1. Blood lymphocyte beta-adrenergic receptors in multiple sclerosis
2. Salbutamol-induced increase of airway responsiveness to allergen and reduced protection versus methacoline: Dose response
3. Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand
4. Differential regulation of IFN-gamma, IL-10 and inducible nitric oxide synthase in human T cells by cyclic AMP-dependent signal transduction pathway
5. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases
6. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants
7. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
8. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy
9. Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype
10. Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40
11. Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein
12. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: An additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors
13. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor
14. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy
15. Interferon beta in multiple sclerosis: Is IL-12 suppression the key?
16. Immunological mechanisms in multiple sclerosis
17. Differential regulation of rheumatoid synovial cell interleukin-12 production by tumor necrosis factor alpha and CD40 signals
18. Monocytes in multiple sclerosis: Phenotype and cytokine profile
19. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12
20. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells
21. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses
22. The beta2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: Mechanisms of action
23. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis
24. Multiple sclerosis: Levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment
25. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12
26. Exacerbations of multiple sclerosis in patients treated with gamma interferon
27. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs
28. Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells
29. The control of T cell responses by dendritic cell subsets
30. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease
31. Regulation of IL-17, IFN-gamma and IL-10 in human CD8(+) T cells by cyclic AMP-dependent signal transduction pathway
32. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis
33. Increased expression of B7-1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease
34. Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigen-presenting cells
35. The role of IL-12 in the induction of organ-specific autoimmune diseases
36. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
37. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis
38. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: Relevance to IFN-beta-1b therapeutic effects in multiple sclerosis
39. Beta-adrenergic agonists suppress chronic/relapsing experimental allergic encephalomyelitis (CREAE) in Lewis rats
40. Increased expression of high affinity IL-2 receptors and beta-adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis